The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | LEVERAGE: obinutuzumab, lenalidomide & venetoclax in patients with advanced-stage FL
Chan Cheah, MBBS, FRACP, FRCPA, DMSc, Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia, comments on the encouraging results of the LEVERAGE trial (NCT03980171), a multicenter study investigating the efficacy of obinutuzumab, lenalidomide, and venetoclax in treatment-naive patients with advanced-stage follicular lymphoma (FL). Dr Cheah highlights the regimen’s high complete metabolic response rate (86%) and progression-free survival (PFS) of 92% at two years. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI generated)
The LEVERAGE trial was a three-drug biologic triplet being used in patients with treatment-naive follicular lymphoma. So we included 50 patients with GELF-positive FL and the treatment combination was fixed-duration obinutuzumab, lenalidomide, and venetoclax, so non-chemotherapy triplet. I think the take-home is that the regimen was active, the complete metabolic response rate after six cycles of therapy was 86%, which is pretty encouraging and comparable, if not better, to chemoimmunotherapy...
The LEVERAGE trial was a three-drug biologic triplet being used in patients with treatment-naive follicular lymphoma. So we included 50 patients with GELF-positive FL and the treatment combination was fixed-duration obinutuzumab, lenalidomide, and venetoclax, so non-chemotherapy triplet. I think the take-home is that the regimen was active, the complete metabolic response rate after six cycles of therapy was 86%, which is pretty encouraging and comparable, if not better, to chemoimmunotherapy. We did have obinutuzumab maintenance after that for responders, and we had a two-year PFS of around 92%, which I think is better than historic control of chemoimmunotherapy. We did see a little bit of hematologic toxicity though, and a few patients had to discontinue early. So that was one of the things that we observed is unsurprisingly from the combination of lenalidomide and venetoclax and obinutuzumab, we saw neutropenia, but it was manageable. And so patients did generally quite well. So encouraging data. We’re planning to look at that in some more detail with some more in-depth molecular analyses, including dynamic changes in ctDNA at future conferences.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Dizal: Consultancy, Honoraria; AstraZeneca: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Other: Travel expenses, Speakers Bureau; Gilead: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; Janssen: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; BeiGene: Consultancy, Honoraria, Other: travel expenses, Speakers Bureau; Lilly: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Roche: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Other: Travel expenses, Research Funding, Speakers Bureau; AbbVie: Consultancy, Honoraria, Research Funding, Speakers Bureau; MSD: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Menarini: Consultancy, Honoraria; Sobi: Consultancy, Honoraria; Regeneron: Consultancy, Honoraria; Genmab: Consultancy, Honoraria, Speakers Bureau; BMS: Consultancy, Honoraria, Research Funding.
